Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Gabapentin changes risk for at least one adverse event per patient compared with pregabalin (very low certainty).
1 finding from 1 review
Risk for at least one adverse drug reaction (ADR) per participant · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Kappa‐opioid agonists may leads to higher risk for at least one adverse drug reaction (ADR) per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Ondansetron changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per participant ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Cromolyn sodium changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Topical capsaicin may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · health problem or population
Summary of findings table ‐ GABA‐analogues showed no clear difference in risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
Summary of findings table ‐ Naltrexone may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per participant ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: need for reoperation/ reimplantation · adults with chronic pain
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: need for reoperation/ reimplantation · adults with chronic pain
The review found no eligible studies for this question.
2 findings from 1 review
Intervention not reported
Intervention Total studies: 9 Total participants: 883 · adults with malignant pleural effusion Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo Comparator…
The intervention led to lower intervention Total studies: 9 Total participants: 883; GRADE not reported.
1 finding from 1 review
no estimate extracted
9 participants
GRADE not reported
Intervention not reported
Talc slurry (8 RCTs, 850 participants) · adults with malignant pleural effusion Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo Comparator…
1 finding from 1 review
Intervention not reported
Talc poudrage (2 RCTs, 380 participants) · adults with malignant pleural effusion Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo Comparator…
1 finding from 1 review
Intervention not reported
Bleomycin (1 RCT, 33 participants) · adults with malignant pleural effusion Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo Comparator…
1 finding from 1 review